By Hannah Waters
By its name alone, the Pap smear sounds like an uncomfortable procedure. Say it aloud: Pap smear. And it’s not too pretty to experience either. You put on a paper dress, slip your feet into stirrups, and spread your legs so a gynecologist can insert a metal duck-bill-shaped speculum (which, if you’re lucky, she’s has taken care to warm up beforehand) into your vagina. Then she swabs your cervix with a long Q-tip to collect a few cells, which she’ll examine under the microscope for abnormal growth that could develop into cancer.
It’s a procedure inconvenient and uncomfortable enough that many women chronically avoid having it done, despite the recommendation to get the cervical cancer test every three years. But it’s incredibly important for women’s health: since the Pap smear’s introduction in the 1950s, cervical cancer diagnoses and deaths have gone down 60 percent, saving thousands upon thousands of lives.
But the classic test now has some competition. In late April, the FDA approved a new test to be used interchangeably with (or replace) the Pap smear to screen for cervical cancer. Where the Pap looks for early signs of cancer in cervical cells, the new test, called the “cobas HPV test,” looks for a common cause of cervical cancer: human papillomavirus (HPV). HPV is a very common sexually transmitted disease, carried by 40 percent of U.S. women ages 14 to 59 at any given time, that causes around 90 percent of all cervical cancers.The premise is logical: Instead of waiting for cervical cancer to develop, go after the cause to nip it in the bud. And according to Roche’s clinical trial data, their new test is better than the Pap smear at identifying early signs of cervical cancer in women older than 25 years.
However, the trial may have overlooked a particularly high-risk group: young women between the ages of 25 and 29. So says a coalition of 17 patient and women’s health groups, which sent a letter to the FDA opposing the test’s approval. As a group, women ages 25 to 29 are more likely to carry HPV but less likely to have cancer, putting them at high risk for receiving a false positive on the new test. These women are then sent in for unnecessary follow-up procedures that could do them physical harm and scare them away from returning to the gynecologist for their next check-up.
This extra risk to younger women should be evident from the clinical trial data. But because it included relatively few women ages 25 to 29 and only observed them for three years, the test’s ineffectiveness in this age group is hidden, the coalition says.
“The risks that come with this decision really affect younger women more than others,” said Anna Mazzucco, scientific advisor at the National Center for Health Research, who organized the coalition’s letter. “That’s why we’re so concerned that there were not enough data on young women. We really do not understand this decision.”
There are more than 100 known strains of HPV, and around 40 of them are transmitted sexually. Most show no symptoms and are incredibly common, especially in women, but a handful of them can cause cervical cancer. When these strains of HPV infect cervical cells, they can cause those cells to grow abnormally and, over 10 to 15 years, those abnormal cells can develop into cancer.
Most HPV viruses, however, clear up on their own within two years. By the time a woman reaches her thirties, most of the strains collected in her sexually active twenties should have resolved themselves. The viruses that stick around for more than a few years are the ones to worry about; those are the ones that have managed to escape her immune system and continue to drive abnormal cell growth.
A Pap smear can detect those abnormally growing cells at a very early stage, when they are growing strangely but are not yet cancerous. That is why both cancer deaths and diagnoses went down after its introduction.
The cobas HPV test, on the other hand, detects the 14 strains of HPV that present the highest cancer risk, including two strains (HPV-16 and HPV-18) that alone cause around 70 percent of cervical cancers. Like the Pap smear, it relies on a swab of cells from a woman’s cervix. But instead of identifying precancerous cells, it detects the DNA of these cancer-causing viruses.
Roche compared its test with the standard in its clinical trial by taking cervical swabs from some 40,000 women, and sending each sample for both a Pap smear and cobas HPV test. Around 10.5 percent of the women in the study, ranging from age 25 to greater than 50 years, were positive for HPV, while 6.4 percent had an abnormal Pap smear. Women who tested positive with either method received additional screening to confirm whether they really had precancerous cells or if it was a false positive. When the results from all ages were pooled, the cobas HPV test was able to identify more women with early signs of cancer, according to Roche’s data.
The data Roche presented to the FDA did not break down the results by age, but there is reason to be concerned that young women were not well represented. Despite their increased risk, only 16 percent of the women were ages 25 to 29; compare that to the 54 percent of women older than 40 years. And those younger women tested positive for HPV almost twice as frequently: 21.1 percent versus 11.6 percent of women 30-39 years old.